Accendra Health (NYSE:ACH – Get Free Report) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.
Several other brokerages have also issued reports on ACH. Robert W. Baird lowered Accendra Health from an “outperform” rating to a “neutral” rating and set a $1.50 price target on the stock. in a research note on Tuesday, August 11th. UBS Group reduced their price objective on shares of Accendra Health from $4.50 to $1.50 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Accendra Health in a research note on Tuesday. Finally, Citigroup downgraded shares of Accendra Health from a “buy” rating to a “neutral” rating and dropped their target price for the company from $4.50 to $1.50 in a research report on Monday, August 10th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Accendra Health has a consensus rating of “Reduce” and an average target price of $1.50.
View Our Latest Stock Analysis on Accendra Health
Accendra Health Stock Down 2.7%
Shares of NYSE ACH opened at $0.28 on Tuesday. The company has a market capitalization of $21.17 million, a PE ratio of 1.23 and a beta of 1.60. Accendra Health has a twelve month low of $0.19 and a twelve month high of $4.69. The firm has a fifty day simple moving average of $0.66 and a 200 day simple moving average of $2.14.
Accendra Health (NYSE:ACH – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). Accendra Health had a negative net margin of 11.41% and a negative return on equity of 4.02%. The firm had revenue of $613.23 million for the quarter. As a group, equities analysts expect that Accendra Health will post -0.03 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Accendra Health
A number of large investors have recently modified their holdings of ACH. Walleye Capital LLC acquired a new position in Accendra Health during the 1st quarter valued at about $27,000. Hsbc Holdings PLC purchased a new stake in shares of Accendra Health in the first quarter worth approximately $34,000. Corient Private Wealth LP purchased a new stake in shares of Accendra Health in the second quarter worth approximately $40,000. Abel Hall LLC bought a new position in shares of Accendra Health in the first quarter valued at approximately $44,000. Finally, Keybank National Association OH purchased a new position in shares of Accendra Health during the first quarter valued at approximately $46,000.
About Accendra Health
Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.
Featured Articles
- Five stocks we like better than Accendra Health
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Accendra Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accendra Health and related companies with MarketBeat.com's FREE daily email newsletter.
